A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants

Inclusion Criteria: * Body mass index (BMI) within the range of 18 to 32 kg/m\^2, inclusive * Negative hepatitis panel and negative HIV antibody screens * Negative screening test for latent Mycobacterium tuberculosis infection * Able to consume the high-fat meal within the protocol-specified time period and willing to consume 100% of the high-fat meal * Able to fast for 8 hours prior to dosing Exclusion Criteria: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, or psychiatric disorder * Personal or family history of congenital long QT syndrome * History of significant hypersensitivity, intolerance, or allergy to any drug * History of acute GI symptoms * History of ophthalmological disease or clinically significant abnormality in the ophthalmic examination * Have significantly impaired hepatic function * Female who is pregnant or breastfeeding or intending to become pregnant during the study or within 90 days following the final ZN-A-1041 administration * Have a QTc interval corrected through use of Fredericia's formula \>450 millisecond (msec), PR interval \>210 msec, QRS complex \>120 msec, or heart rate \<50 beats per minute (bpm) * Use of any drugs known to be moderate or strong inhibitors or inducers of CYP3A or CYP2C8 * Poor peripheral venous access * History of malignancy within 5 years prior to enrollment